RxDoctor Payments Data

Amy Blancke

Nurse Practitioner · Fort Worth, TXNPI 1538729421

Payments from drug & device makers

$7,500in general payments, 2019–2025

Across 227 payments — averaging $33.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Amgen$556
  • E.r. Squibb & Sons, L.L.C.$534
  • Merck$521
  • Novartis$487
  • Scpharmaceuticals Inc.$471
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$1,18616%
  • Food & beverage$6,29984%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,500 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$28,355
Medicare patients
250
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$133,048
EntrestoSacubitril/Valsartan32$42,737
XareltoRivaroxaban23$29,641
Repatha SureclickEvolocumab16$22,755
JardianceEmpagliflozin12$12,595
VascepaIcosapent Ethyl13$9,859
Ranolazine ErRanolazine86$6,754
Metoprolol Succinate206$3,008
Nifedipine ErNifedipine79$1,488
Isosorbide Mononitrate ErIsosorbide Mononitrate82$1,073
Potassium Chloride65$1,004
ClopidogrelClopidogrel Bisulfate56$712
Olmesartan Medoxomil54$647
Rosuvastatin Calcium76$638
Ezetimibe37$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$416$133,04896 claims
NovartisEntresto$487$42,73732 claims
Johnson & JohnsonXarelto$18$29,64123 claims
Boehringer IngelheimJardiance$155$12,59512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →